Business
ANGLE: 7th Peer Reviewed Publication On Parsortix
ANGLE: 7th Peer Reviewed Publication On Parsortix.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 7443T Angle PLC 17 October 2017 \n\n\n\n\n\nFor immediate release\n\n\n 17 October 2017\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nSEVENTH PEER REVIEWED PUBLICATION ON ANGLE'S PARSORTIXTM SYSTEM \n \nParsortixTM system outperforms other approaches to harvest circulating tumour cells from the blood of clear cell renal cell carcinoma patients \n \nThe ParsortixTM system demonstrated the highest recovery rate and the highest purity of all evaluated systems \n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, today announces that its ParsortixTM system is the subject of a peer-reviewed publication in the journal Oncotarget detailing work undertaken by ANGLE's customer, University Hospital Muenster, Germany (Muenster).\n \nMuenster undertook a detailed evaluation of performance of four different types of systems in their ability to harvest circulating tumour cells (CTCs) for clear cell renal cell carcinoma (kidney cancer) patients. The approaches evaluated were (i) antibody-based capture (EpCAM), (ii) density-based separation and CD45 negative depletion (removal of white blood cells), (iii) negative enrichment (removal of white blood cells) and density based centrifugation, and (iv) the ParsortixTM system.\n \nThe ParsortixTM system out-performed all the other systems on all the measures investigated and was recommended by the investigators as the system to use in patients with such renal cell carcinomas. In particular, the ParsortixTM system had both the highest cell recovery and the highest purity of all the approaches studied.\n \nThe publication is available at https://angleplc.com/library/publications/\n \nGlobally, the incidence of renal cell carcinoma varies widely from region to region, with the highest rates observed in the Czech Republic and North America. In the United States, there are approximately 64,000 new cases and almost 14,000 deaths from renal cell carcinoma each year. In the European Union, there were approximately 84,000 cases of renal cell carcinoma and 35,000 deaths due to kidney cancer in 2012. \n \n \nANGLE Founder and Chief Executive, Andrew Newland, commented:\n\"This published study further demonstrates that the ParsortixTM system outperforms others for harvesting circulating tumour c...